Piramal Pharma Future Growth
Future criteria checks 4/6
Piramal Pharma is forecast to grow earnings and revenue by 100.7% and 13.4% per annum respectively. EPS is expected to grow by 103.7% per annum. Return on equity is forecast to be 8% in 3 years.
Key information
100.7%
Earnings growth rate
103.7%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 13.4% |
| Future return on equity | 8.0% |
| Analyst coverage | Low |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 105,261 | 8,080 | 7,030 | N/A | 4 |
| 3/31/2025 | 92,972 | 5,061 | 5,155 | N/A | 4 |
| 3/31/2024 | 81,131 | 1,178 | 2,678 | N/A | 5 |
| 12/31/2023 | 78,435 | -333 | N/A | N/A | N/A |
| 9/30/2023 | 76,009 | -1,336 | -992 | 8,655 | N/A |
| 6/30/2023 | 74,096 | -1,760 | N/A | N/A | N/A |
| 3/31/2023 | 71,427 | -1,865 | -4,809 | 4,839 | N/A |
| 12/31/2022 | 72,228 | -325 | -6,634 | 3,382 | N/A |
| 9/30/2022 | 69,535 | 2,210 | N/A | N/A | N/A |
| 6/30/2022 | 67,532 | 2,626 | N/A | N/A | N/A |
| 3/31/2022 | 67,341 | 3,760 | -1,231 | 7,664 | N/A |
| 3/31/2021 | 58,868 | 7,708 | -43 | 5,516 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPLPHARMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: PPLPHARMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PPLPHARMA is expected to become profitable in the next 3 years.
Revenue vs Market: PPLPHARMA's revenue (13.4% per year) is forecast to grow faster than the Indian market (10% per year).
High Growth Revenue: PPLPHARMA's revenue (13.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPLPHARMA's Return on Equity is forecast to be low in 3 years time (8%).